Tagrisso 40MG Tablet (10’s) is a targeted therapy medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR) gene. The active ingredient in Tagrisso is Osimertinib, which is formulated in a 40mg dosage per tablet. This medication is designed to inhibit the growth of cancer cells by blocking the signals that promote their proliferation. Tagrisso is particularly effective for patients with advanced or metastatic NSCLC who have developed resistance to earlier EGFR inhibitors, making it a crucial option in personalized cancer treatment. The tablet is typically taken once daily, with or without food, and is part of a comprehensive treatment plan that may include other therapies. Understanding the composition and purpose of Tagrisso is essential for patients and healthcare providers alike, as it plays a significant role in managing lung cancer effectively.